PACB vs TSM Stock Comparison

TSM currently leads PACB in this stock comparison, with AIQ scores of 68 vs 48. The clearest difference is value, while PACB has the stronger momentum profile.

Market data as of Nov 18, 2026 market close· AIQ score gap 20 points
PACB
Healthcare
vs
TSM
Technology
PACB
Pacific Biosciences of California, Inc.
Price
$1.83
Day move
+0.55%
AIQ Score
48/100
Best edge
Momentum
Sector
Healthcare
TSM
Taiwan Semiconductor Manufacturing Company Limited
Leads
Price
$363
Day move
+0.81%
AIQ Score
68/100
Best edge
Value
Sector
Technology

What is the main difference between PACB and TSM?

TSM leads the current stock comparison as Taiwan Semiconductor Manufacturing Company Limited, with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Pacific Biosciences of California, Inc. vs Taiwan Semiconductor Manufacturing Company Limited

Data as of Nov 18, 2026· market close· Cross-sector · Healthcare vs Technology· Coverage 65/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 8/10

TSM leads

TSM leads by 20 AIQ points, primarily on Value and Quality, but the lead has narrowed from 28 points over 30 sessions.

Competitive: 5 of 6 evidence groups support TSM, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 5 of 6Comparison trend: Weakening
PACB

Pacific Biosciences of California, Inc.

AIQ Score
48/100
AIQ Edge Score
4/10
TSM

Taiwan Semiconductor Manufacturing Company Limited

Leads
AIQ Score
68/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors TSM over PACB, 68 versus 48 as of Nov 18, 2026. TSM's advantage is driven primarily by stronger value and quality, while PACB holds the stronger momentum profile. TSM also shows the weaker technical structure relative to its 50-day moving average. 5 of 6 covered evidence groups favor TSM today, and the comparison is rated Competitive on stability: the leader's advantage has been narrowing. TSM lead: Weakening — the AIQ differential moved from 28 to 20 points over 30 sessions.

Compare Pacific Biosciences of California, Inc. and Taiwan Semiconductor Manufacturing Company Limited across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

PACB
-91.9%
TSM
+210.3%

Total return comparison

Growth of $10,000, distributions reinvested

PACB $807 · TSM $31,032

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare PACB and TSM against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

PACB advantage
0
TSM advantage
  • Value23 vs 67
    TSM +44
  • Quality32 vs 74
    TSM +42
  • Risk Resilience24 vs 57
    TSM +33
  • Momentum84 vs 67
    PACB +17

5 of 6 evidence groups favor TSM. TSM’s edge is concentrated in value and quality; PACB keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

PACB0 AIQ

Largest factor move: Value -1, not enough on its own to move the overall score.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
  • Stochastic Oversold Bounce — bullish, momentum, short horizon
TSM+1 AIQ

Largest factor move: Momentum +1

New signals

  • Price Lost 200-Day MA — bearish, trend, long horizon

TSM's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — PACB and TSM both carry a full feed there.

The central trade-off

TSM (Taiwan Semiconductor Manufacturing Company Limited): the stronger current systematic profile, led by value and quality.

PACB (Pacific Biosciences of California, Inc.): the counter-case, on momentum, technicals — but at materially higher volatility, 114.1% against 61.7%.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

TSM

TSM on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

TSM

TSM on combined revenue and EPS growth.

Value

TSM

TSM on the peer-relative Value factor, by 44 points.

Momentum

PACB

PACB on the Momentum factor, by 17 points.

Lower downside

TSM

TSM on Risk Resilience, by 33 points.

Analyst upside

TSM

TSM on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasurePACBTSMNote
Implied upside to target+5.2%+58.9%TSM has more room
Target dispersion+59.7%+26.9%Lower is tighter analyst agreement
ConsensusHoldBuyContext, not a primary driver
Analysts covering822Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

5 of 6 covered evidence groups favor TSM. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreTSM48 vs 68
FundamentalsTSMon balancerevenue growth 4% vs 17.6%; EPS growth 14.3% vs 8%; TTM ROE 61.7% vs 10.9%; gross margin 34.5% vs 65.8%; operating margin -99.6% vs 57.9% — TSM takes 3 of 5 decided legs, not all of them
ValuationTSMValue 23 vs 67
TechnicalsPACBPrice vs 50-day -8.7% vs -15.7%; vs 200-day 22.4% vs -1.1%
Risk ResilienceTSMRisk Resilience 24 vs 57
Analyst expectationsTSMTarget upside 5.2% vs 58.9%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of PACB and TSM and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 20 points. (supports the conclusion holding)
  • 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on TSM.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

TSM lead: Weakening — the AIQ differential moved from 28 to 20 points over 30 sessions.

Jun 1PACB leads above the line · TSM leads belowNov 18
Today
TSM +20
48 vs 68
7 sessions ago
TSM +19
49 vs 68
30 sessions ago
TSM +28
44 vs 72
90 sessions ago
TSM +37
30 vs 67

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

PACBConflicted

3 bullish / 3 bearish / 1 neutral, conflicted

Only PACB

  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • Stochastic Oversold Bounce — bullish, momentum, short horizon
TSMConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only TSM

  • Price Lost 200-Day MA — bearish, trend, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon

Both carry 3 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, Beta Spike Warning.

TSM leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

PACBNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.55%, AIQ 0 points).

TSMConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.81%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1PACB closes the Value gap — currently 44 points behind, the largest single contributor to TSM's edge.
  2. 2PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3TSM's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 8 points over 30 sessions, and a further 20-point move would eliminate TSM's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

TSM leads on balance
MetricPACBTSM
Revenue growth (YoY)4%17.6%
EPS growth (YoY)14.3%8%
Gross margin34.5%65.8%
Operating margin-99.6%57.9%
Return on equity (TTM)61.7%10.9%
Debt to equity-11.490.14

Performance

Split across windows
MetricPACBTSM
1 week (5 sessions)-13.1%6.2%
1 month (20 sessions)13.3%-3.4%
3 months (63 sessions)62%-7.5%
6 months (126 sessions)75%-1.4%
Year to date4.8%31.2%
1 year (252 sessions)12.6%37.2%

Technicals

PACB has the stronger structure
MetricPACBTSM
RSI (14)43.145.3
ADX (14)27.429.2
Price vs 50-day-8.7%-15.7%
Price vs 200-day22.4%-1.1%
Volatility (1M, annualized)114.1%61.7%

Risk

TSM is the more resilient
MetricPACBTSM
Beta2.12.16
Sharpe ratio0.610.95
Sortino ratio0.961.37
Max drawdown-58.4%-27.3%
Current drawdown-32.4%-17.9%
Annualized volatility93.5%41.8%
Value at risk (95%)-9%-4.2%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, PACB or TSM?

On the Algovestiq AIQ Score, TSM is the stronger of the two as of Nov 18, 2026, scoring 68 against PACB's 48. The edge comes from value and quality. PACB is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is PACB or TSM the better buy right now?

TSM carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Competitive — 5 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor TSM over PACB?

The composite weights Quality, Value, Momentum and Risk Resilience. TSM leads Value by 44 points; TSM leads Quality by 42 points; TSM leads Risk Resilience by 33 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, PACB or TSM?

Analyst price targets imply +5.2% upside for PACB and +58.9% for TSM, so the Street currently favors TSM. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, PACB or TSM?

TSM is the better-valued of the two on the peer-relative Value factor. TSM on the peer-relative Value factor, by 44 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, PACB or TSM?

TSM on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, PACB or TSM?

PACB on the Momentum factor, by 17 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, PACB or TSM?

TSM is the more resilient of the two, so the other name carries the higher downside risk. TSM on Risk Resilience, by 33 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is PACB more profitable than TSM?

The profitability evidence is mixed: gross margin 34.5% vs 65.8%; operating margin -99.6% vs 57.9%; ttm roe 61.7% vs 10.9%. PACB leads on one measure and TSM on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is TSM's lead over PACB getting stronger or weaker?

TSM lead: Weakening — the AIQ differential moved from 28 to 20 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.

What would change the PACB vs TSM verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PACB closes the Value gap — currently 44 points behind, the largest single contributor to TSM's edge; PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; TSM's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; the narrowing continues — the lead has already given back 8 points over 30 sessions, and a further 20-point move would eliminate TSM's advantage entirely.

What do the current signals say about PACB and TSM?

PACB: 3 bullish / 3 bearish / 1 neutral, conflicted. TSM: 2 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on PACB is Golden Cross Active (bullish, long horizon). On TSM it is Golden Cross Active (bullish, long horizon).

Compare PACB and TSM with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.